[HTML][HTML] Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
LAT Bloedon, R Dunbar, D Duffy, P Pinell-Salles… - Journal of lipid …, 2008 - ASBMB
Patients with coronary heart disease or equivalent risk received a single dose of 30, 100,
300, or 500 mg of unformulated D-4F (n= 8, each dose) or placebo (n= 8) under fasting
conditions. An additional 10 patients received 500 mg (n= 8) or placebo (n= 2) with a low-fat
meal. There were no significant trends in any safety parameter. D-4F was detectable in
plasma at all doses with a T max of 30 min, 1 h, and 2 h for 30, 100, and⩾ 300 mg,
respectively. The area under the curve (0− t) was 27.81 ng/hr/ml and 54.71 ng/hr/ml for the …
300, or 500 mg of unformulated D-4F (n= 8, each dose) or placebo (n= 8) under fasting
conditions. An additional 10 patients received 500 mg (n= 8) or placebo (n= 2) with a low-fat
meal. There were no significant trends in any safety parameter. D-4F was detectable in
plasma at all doses with a T max of 30 min, 1 h, and 2 h for 30, 100, and⩾ 300 mg,
respectively. The area under the curve (0− t) was 27.81 ng/hr/ml and 54.71 ng/hr/ml for the …